Nutriband (Nutriband) Days Payable : 0.00 (As of Jan. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Nutriband Days Payable?

Nutriband's average Accounts Payable for the three months ended in Jan. 2024 was $0.00 Mil. Nutriband's Cost of Goods Sold for the three months ended in Jan. 2024 was $0.34 Mil. Hence, Nutriband's Days Payable for the three months ended in Jan. 2024 was 0.00.

The historical rank and industry rank for Nutriband's Days Payable or its related term are showing as below:

NTRB's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 150.695
* Ranked among companies with meaningful Days Payable only.

Nutriband's Days Payable stayed the same from Jan. 2023 (0.00) to Jan. 2024 (0.00). stayed the same

Nutriband Days Payable Historical Data

The historical data trend for Nutriband's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nutriband Days Payable Chart

Nutriband Annual Data

Trend

Jan16

Jan17

Jan18

Jan19

Jan20

Jan21

Jan22

Jan23

Jan24

Days Payable

Get a 7-Day Free Trial

Nutriband Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
Days Payable	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Nutriband's Days Payable

For the Biotechnology subindustry, Nutriband's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nutriband's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nutriband's Days Payable distribution charts can be found below:

* The bar in red indicates where Nutriband's Days Payable falls into.

Nutriband Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Nutriband's Days Payable for the fiscal year that ended in Jan. 2024 is calculated as

	Days Payable (A: Jan. 2024 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Jan. 2023 )	+	Accounts Payable (A: Jan. 2024 ))	/	count )	/	Cost of Goods Sold (A: Jan. 2024 )	*	Days in Period
=	( (0	+	0)	/	1 )	/	1.223	*	365
=	0					/	1.223	*	365
=	0.00

Nutriband's Days Payable for the quarter that ended in Jan. 2024 is calculated as:

	Days Payable (Q: Jan. 2024 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Oct. 2023 )	+	Accounts Payable (Q: Jan. 2024 ))	/	count )	/	Cost of Goods Sold (Q: Jan. 2024 )	*	Days in Period
=	( (0	+	0)	/	1 )	/	0.344	*	365 / 4
=	0					/	0.344	*	365 / 4
=	0.00

Nutriband Days Payable Related Terms

Thank you for viewing the detailed overview of Nutriband's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Nutriband (Nutriband) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nutriband Inc (NAS:NTRB) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

9WV:Germany

Address

121 South Orange Avenue, Suite 1500, Orlando, FL, USA, 32801

Website

https://www.nutriband.com

Nutriband Inc is primarily engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's lead product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.

Executives

Michael Davidov	director	60 EAST 42 STREET, NEW YORK NY 10165
Serguei Melnik	director, 10 percent owner, officer: Chief Financial Officer
Gareth Sheridan	director, 10 percent owner, officer: CEO	6064 CENTRAL COLLEGE RD., NEW ALBANY OH 43054
Vitalie Botgros	director, 10 percent owner, officer: Chairman of the BOD	GREGERSTR 36B, FISHAMEND C4 2401